Free Trial
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel
NASDAQ:IMVT

Immunovant Q2 2027 Earnings Date & Estimates

Immunovant logo
$28.71 -0.77 (-2.61%)
Closing price 04:00 PM Eastern
Extended Trading
$28.54 -0.18 (-0.61%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Immunovant is estimated to report Q2 2027 earnings on Monday, November 9, 2026, before market opens. The conference call is scheduled for 8:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q2 2027
Announcement Date
Time
Before Market Opens
Conference Call
8:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Immunovant in Q2 2027

Immunovant is expected to post earnings of -$0.73 per share on revenue of $7.10 million. In the same quarter a year earlier Immunovant reported -$0.73 per share. Immunovant last reported on August 6, 2026, posting -$0.75 per share and missing the -$0.6289 consensus estimate. Immunovant has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.73
Expected Revenue
$7.10 million
Prior-Year EPS
-$0.73

Recent Track Record

Last Reported
Q1 2027
Last Quarter EPS
-$0.75 (Missed by -$0.1211)
Last Quarter Revenue
$7.10 million
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q2 2027 Call

Immunovant Q2 2027 Earnings FAQ

Immunovant (NASDAQ:IMVT) is estimated to report Q2 2027 earnings on Monday, November 9, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Immunovant's Q2 2027 earnings conference call is scheduled for Monday, November 9, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Immunovant to post earnings of -$0.73 per share for Q2 2027.

The consensus revenue estimate for Immunovant is $7.10 million for Q2 2027.

Immunovant Earnings Headlines

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm
October 12 at 7:35 PM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-immunovant-inc-to-contact-law-firm-302906196.html
Immunovant (NASDAQ:IMVT) COO Sells $71,846.46 in Stock
October 12 at 4:52 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31109835
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.tc pixel
October 13 at 1:00 AM  |  Banyan Hill Publishing (Ad)
Insider Selling: Immunovant (NASDAQ:IMVT) CTO Sells $122,116.54 in Stock
October 12 at 4:09 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31109585
IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law
October 11 at 6:00 PM  |  businesswire.comhttps://www.businesswire.com/news/home/20261011801778/en/IMVT-Investors-with-100000-in-Losses-Have-Opportunity-to-Join-Immunovant-Inc.-Fraud-Investigation-with-SBS-Law/
IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class
October 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/imvt-roiv-stocks-slide-argenx-173332870.html
See More Immunovant Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immunovant? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunovant and other key companies, straight to your email.

About Immunovant

Immunovant (NASDAQ:IMVT) is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune diseases. The company’s approach centers on targeting the neonatal Fc receptor (FcRn), a protein involved in the recycling of immunoglobulin G antibodies that can contribute to autoimmune activity.

Immunovant’s lead product candidate is batoclimab (IMVT-1401), a fully human monoclonal antibody designed to reduce circulating disease-causing antibodies. The company has evaluated batoclimab in several autoimmune conditions, including generalized myasthenia gravis and Graves’ disease, and has also pursued development in other antibody-mediated disorders. Its pipeline additionally includes IMVT-1402, a next-generation FcRn inhibitor intended for subcutaneous administration.

Immunovant was established as a subsidiary of Roivant Sciences and obtained rights to develop its FcRn antibody programs from HanAll Biopharma. The company conducts clinical development primarily through studies in the United States and other international markets. Pete Salzmann has served as Immunovant’s president and chief executive officer.

View Immunovant Profile
Earnings Tools